143 related articles for article (PubMed ID: 7744585)
1. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.
Cohen AD; Gopas J; Karplus G; Cohen Y
Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
[TBL] [Abstract][Full Text] [Related]
4. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
Einarsson R; Lindman H; Bergh J
Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
[TBL] [Abstract][Full Text] [Related]
5. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
Schuurman JJ; Bong SB; Einarsson R
Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
[TBL] [Abstract][Full Text] [Related]
6. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
7. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
Hu XC; Day W; Jones B; Loo WT; Chow LW
Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
[TBL] [Abstract][Full Text] [Related]
8. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
11. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
Willsher PC; Beaver J; Blamey RW; Robertson JF
Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
[TBL] [Abstract][Full Text] [Related]
12. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma.
Yao WJ; Chang CJ; Chan SH; Chow NH; Cheng HL; Tzai TS; Lin SN
Anticancer Res; 1995; 15(6B):2819-23. PubMed ID: 8669871
[TBL] [Abstract][Full Text] [Related]
13. How can treatment response be measured in breast cancer patients?
van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
[TBL] [Abstract][Full Text] [Related]
14. Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer.
Bremer K; Eklund G; Björklund B
Anticancer Res; 1996; 16(2):905-9. PubMed ID: 8687149
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
[TBL] [Abstract][Full Text] [Related]
16. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
Eskelinen M; Lipponen P; Syrjänen K
Anticancer Res; 1992; 12(1):91-5. PubMed ID: 1567186
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
[TBL] [Abstract][Full Text] [Related]
18. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
19. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
Silver HK; Archibald BL; Ragaz J; Coldman AJ
Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
[TBL] [Abstract][Full Text] [Related]
20. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting.
Briasoulis E; Andreopoulou E; Tolis CF; Bairaktari E; Katsaraki A; Dimopoulos MA; Fountzilas G; Seferiadis C; Pavlidis N
Cancer; 2001 Mar; 91(5):909-17. PubMed ID: 11251942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
